Bepotastine besilate is a non-sedating, antagonist of the histamine H1 receptor that acts by suppressing the migration of eosinophils into inflamed tissues. The Phase 2 randomised placebo-controlled parallel-group
As a part of the agreement, Gilead will receive antibodies produced by AnaptysBio by the means of SHM-XEL platform, for the development and commercialization. AnaptysBio president and chief
Under the collaboration, GSK integrates its expertise in medicinal chemistry with Yale’s work on proteolysis targeting chimeric molecules (PROTACs). The PROTAC technology directs disease-causing proteins to a cell’s
The grant will continue to support the research previously supported by a Phase I SBIR grant, the company said. With the grant, ImmuVen will continue development of its
The integrated cartridge system comprises necessary reagents to perform the assay and predict the presence of infection in the sample. The key benefits of the platform include, on-demand
Elelyso, derived from ProCellEx, is an enzyme replacement therapy (ERT) for the long-term treatment of adults with type 1 Gaucher disease. The plant cell-expressed drug is a form
The antioxidants in Sambucus Nigra will enhance the immune system against coughs, colds, flu and bacterial and viral infections. The company’s new pectin-based gummy bears contain concentrated Sambucus
The bioLock software is configured to work with Zvetco Verifi P5000 fingerprint scanners, resulting in biometric verification of selected users’ identities when performing sensitive or mission-critical functions. The
The SYNERGY trial is designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in RA patients. The company
The new platform developed by Kadimastem permits usage of human functional tissues produced industrially from pluripotent stem cells as a way to search for potential new drugs. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.